falsefalse

Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life - Episode 7

Adverse Events Seen With JAK Inhibitors for Myelofibrosis

January 5, 2024
Christine Cooper, RN, BSN

,
Aaron Gerds, MD, MS

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      EP. 1: Diagnosing Myelofibrosis
      EP. 2: Assessing Risk Level of Patients With Myelofibrosis
      EP. 3: Educational Resources for Patients Diagnosed With Myelofibrosis
      EP. 4: Key Patient Goals for Myelofibrosis Management
      EP. 5: Management of Anemia in Patients With Myelofibrosis
      EP. 6: Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis
      Now Viewing
      EP. 7: Adverse Events Seen With JAK Inhibitors for Myelofibrosis
      EP. 8: Assessing Treatment Response in Patients With Myelofibrosis
      EP. 9: Best Approaches to Switching Therapies for a Patient With Myelofibrosis
      EP. 10: Dosing JAK Inhibitors in Patients With Myelofibrosis
      EP. 11: Key Takeaways for Patients With Myelofibrosis

      Related Content:

      Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life
      Key Takeaways for Patients With Myelofibrosis
      Dosing JAK Inhibitors in Patients With Myelofibrosis
      Best Approaches to Switching Therapies for a Patient With Myelofibrosis
      x